1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Anaveon AG

Have updates for this profile?  Please contribute data

About Employee data
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2017

Location

Basel Switzerland

Primary Industry

Biotechnology

About

Founded in 2017 and based in Basel, Switzerland, Anaveon AG is a biotechnology company that develops IL-2 Receptor Agonist, a protein that mimics Interleukin 2 to induce the human immune system to fight infection and tumors.
Current Investors
UZH Life Sciences Fund, Novartis Venture Fund, Syncona Limited

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.anaveon.com
Company Stage
Series B
Total Amount Raised
Subscriber access only

Employee Data

Employee Graph

Want to see the Employee Count?

Request a demo for full access to this profile.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo